3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
7
Phase 1/2
6
Phase 2
4
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Pancreatic Neoplasms
74
Carcinoma, Non-Small-Cell Lung
73
Breast Neoplasms
39
Lung Neoplasms
31
Urinary Bladder Neoplasms
28
Nasopharyngeal Carcinoma
28
Ovarian Neoplasms
25
Neoplasm Metastasis
21
Cholangiocarcinoma
18
Triple Negative Breast Neoplasms
16
Neoplasms
16
Lymphoma, Large B-Cell, Diffuse
13
Gallbladder Neoplasms
13
Biliary Tract Neoplasms
13
Uterine Cervical Neoplasms
12
Recurrence
12
Carcinoma, Transitional Cell
12
Nasopharyngeal Neoplasms
11
Parkinson Disease 4, Autosomal Dominant Lewy Body
10
Fallopian Tube Neoplasms
10
Non-Muscle Invasive Bladder Neoplasms
9
Lymphoma
7
Carcinoma
7
Bile Duct Neoplasms
7
Lymphoma, Non-Hodgkin
6
Adenocarcinoma
6
Carcinoma, Hepatocellular
5
Adenocarcinoma of Lung
5
Neoplasms by Site
4
Urothelial Cancer
3
Interventions
Rituximab
67
Cyclophosphamide
39
Vincristine
33
Prednisone
31
Doxorubicin
25
Lenalidomide
18
Radiotherapy
16
Bendamustine Hydrochloride
14
Peripheral Blood Stem Cell Transplantation
10
Filgrastim
10
Etoposide
10
Prednisolone
8
tofacitinib
7
obinutuzumab
6
ibritumomab tiuxetan
6
fludarabine
6
VAP-cyclo protocol
6
Mitoxantrone
6
Methylprednisolone
6
Deoxycholic Acid
6
Cytarabine
6
Melphalan
5
Dexamethasone
5
Carmustine
5
ibrutinib
4
fludarabine phosphate
4
R-CHOP protocol
4
Methotrexate
4
Interferon-alpha
4
Idarubicin
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Lymphoma, Follicular
×
Gemcitabine
×
Clear all
NCT01321541
2021-11-19
PIX-R
CTI BioPharma
Phase 3
Completed
312 enrolled
16 charts